🍂 Enjoy the Fall Season! 🍂
MindTheDesk

US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets

Global - Asia Archived • October 6, 2026 •
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas.
New York-listed ArriVent closed down nearly 47 per cent on Tuesday after reporting that its cancer treatment firmonertinib failed to meet its main goal in a phase 3 trial.
Firmonertinib was originally developed by Shanghai Allist Pharmaceuticals to treat non-small...
Source: South China Morning Post | https://www.scmp.com/rss/91/feed - Read Original
"Retirement Health Care"
"Output is a realization of Input."

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!

Sponsored
"Get your business promoted today."